Blog

Successful clinical trial recruitment requires a thorough understanding of the target patient profile, and a key factor within this profile is patient motivation.

The US Food & Drug Administration (FDA) amended requirements for the acceptance of clinical data cllected outside the US to support medical device submissions.

The opportunity for blockchain in healthcare and clinical trials.

Late phase studies are ripe for digitalisation, although not always in the same ways as Phase II and III programs.

Learn how to use biostatistics using RMST in Oncological trials to improve clinical outcomes

NASH ranks among the world’s great emerging health threats

ICON has developed a lab logistics program to reduce costs

Late phase research, once the exception, is becoming the rule. Some post marketing evidence needs can be met with virtual studies, DtP and cyber studies.

There is an increasing demand from sponsors for technology and data-driven solutions to improve site selection, study start- up and patient recruitment.

An insulin injector is significantly safer and easier to use, and therefore leads to fewer complications and better clinical outcomes.

The FDA issued a draft guidance on the Expanded Abbreviated 510(k) program, which describes an optional pathway for certain widely understood device types.

This is the first posting in a three-part series drawn from ICON’s webinar, “Evolving Best Practices for Working with Authors—Authorship and Beyond.”

Find out about the FDA's pathway to assist industry in expediting drug development.

Benefits include better, more personalised, treatment and improved clinical outcomes, with fewer clinic visits and greater independence for patients.

Emerging mHealth technologies are transforming patient care by integrating health data across the healthcare landscape.

Recent approvals of CAR-T immuno-oncology therapies present a market opportunity estimated to grow nearly 50 percent annually over the next decade.

Drug Master File electronic submissions to the FDA deadline is fast approaching.

The FDA announced a proposed programme for publishing certain device malfunction medical device reports.

Artificial intelligence (AI) technology, combined with big data, hold the potential to solve many key clinical trial challenges.

Patient-First Rapid Site Activation can greatly reduce the time and cost spent on non-performing sites by never activating them in the first place.